Skip to main content
Publish date:

Sigilon Therapeutics To Participate In The Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc.

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (SGTX) - Get Sigilon Therapeutics, Inc. Report, a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in a fireside chat during the Jefferies Virtual Healthcare Conference. The fireside chat will take place on Thursday, June 3 at 8:00 a.m. EDT, in a virtual format.

A live webcast of the fireside chat will be accessible under "Events and Presentations" in the Investors & Media page of the Company's website at www.sigilon.com. A replay of the fireside chat will be available at the same location following the event.

About Sigilon TherapeuticsSigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon's product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal diseases and diabetes. The engineered cells are protected by Sigilon's Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Investor ContactsRob WindsorSigilon Therapeutics, Head of Investor Relations robert.windsor@sigilon.com  617-586-3837

Mike BiegaSolebury Trout mbiega@soleburytrout.com 617-913-8890

Media ContactAmy BonannoSolebury Trout abonanno@soleburytrout.com 914-450-0349